For Cillian Murphy, who was at the center of the film world in 2023 as the lead in Christopher Nolan's culturally seismic and ...

When we imagine extreme wealth, private islands spring to mind—tropical paradises located in far-flung corners of the globe, ...

A fancy vivid 10-carat cushion-modified blue diamond – known as the Mediterranean Blue – will appear at Sotheby’s in Geneva on 13 May. As one of the largest ...

Analysts, along with Erik Bissonnette, Co-Head of Technology Investing and Member of the Blue Owl Technology Credit Advisors Investment ...

Diamond rings have long been symbols of wealth, status, and romance. Even today people spend unthinkable amounts of money on engagement rings to profess their love. From wedding bands to collector’s ...

(Bloomberg) -- The boom in M&A activity that dealmakers on Wall Street had hoped for after Donald Trump’s return to the White House may never materialize, according to Oppenheimer & Co.

As interest rates fall, business development companies', or BDCs, return on equity will likely be pressured. Oppenheimer analyzed its BDC coverage to see which names would fare best as rates fall.

Shares of Nektar Therapeutics (NASDAQ:NKTR) added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to Outperform from Perform, citing a favorable valuation setup ahead of a ...

Forbes contributors publish independent expert analyses and insights.